Cardiovascular

Pradaxa antidote goes to FDA

The breakthrough designation therapy drug was the first for its drug class.

BI rare-disease awareness push slated for Saturday

Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.

Poll highlights cholesterol knowledge gap

Poll highlights cholesterol knowledge gap

By

Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.

Five things for pharma marketers to know: Thursday, February 19

Five things for pharma marketers to know: Thursday, February 19

By By

Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.

Specialty medications have PBMs on edge

Specialty medications have PBMs on edge

By

CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.

Five things for pharma marketers to know: Thursday, February 12

Five things for pharma marketers to know: Thursday, February 12

By

Hospira is planning a Lucentis biosimilar, Roche is expanding is cancer diagnostics portfolio, and cholesterol may not be as bad as originally thought (but smoking is worse than ever).

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

By

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Sanofi, Regeneron officially in PCSK9 race

Sanofi, Regeneron officially in PCSK9 race

By

The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.

Roche's scuttled cholesterol drug may work

Clinical trials indicate the CETP works for specific genetic profiles.

Mylan enters generic Diovan fray

The drugmaker launched four doses of the blood pressure medication.

Sanofi, Regeneron field  pre-launch cholesterol IQ poll

Sanofi, Regeneron field pre-launch cholesterol IQ poll

By

The drugmakers, who have an experimental cholesterol medication in the works, are asking consumers what they know about heart health.

Bayer launches respiratory awareness contest

Bayer launches respiratory awareness contest

By

Encouraging competitors to take an artistic approach to "Breathless Moments," the competition is a first for Bayer, which is already working on next year's effort.

Analyses support Pradaxa safety profile

Analyses support Pradaxa safety profile

By

Results of two post-market studies, conducted in part by Boehringer Ingelheim, corroborate the billion-dollar blood thinner's benefit/risk profile.

PCSK9s stalk Merck's Vytorin

PCSK9s stalk Merck's Vytorin

By

A head-to-head comparison between Sanofi and Regeneron's experimental PCSK9 shows alirocumab lowers LDL levels more effectively than Merck's Zetia, which is part of the just-acquitted Vytorin.

Study finds new benefits in highly promising heart drug

A pipeline drug from Novartis has the potential to alter the progression of heart disease and keep patients out of the hospital.

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

By

Merck said in November that a long-running clinical trial finally demonstrated the impact of its Zetia cholesterol-lowering treatment on cardiovascular outcomes.

Five things for pharma marketers to know: Monday, November 17

Five things for pharma marketers to know: Monday, November 17

By

Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.

Five things for pharma marketers to know: Thursday, November 13

Five things for pharma marketers to know: Thursday, November 13

By

Actavis and Allergan are close to a deal in the $60-billionish range; AstraZeneca is working on a Brilinta antidote; scientists find what amounts to a naturally occurring version of Merck's Zetia.

Coalition urges gender-specific heart research

Coalition urges gender-specific heart research

By

The industry-supported group WomenHeart launched a heart failure awareness campaign Wednesday, as well as a push for gender-specific research.

Pradaxa antidote enters Phase III

Testing has already started abroad, and Boehringer says this is the first clinical trial that tests an antidote among patients taking a new oral anticoagulant.

Five things for pharma marketers to know: Friday,  October 17

Five things for pharma marketers to know: Friday, October 17

By

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

Analysts see potential in Novartis's serelaxin

Analysts see potential in Novartis's serelaxin

By

Two regulatory agencies have rejected the drug, but analysts indicate the pipeline acute heart failure treatment could have limited market success.

Five things for pharma marketers to know: Friday, October 3

Five things for pharma marketers to know: Friday, October 3

By

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.

Novartis may have game-changing drug

Novartis may have game-changing drug

By

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

By

Evolocumab holds the FDA's first filed biologics license application for the class.

GAO tallies cost-effective interventions

GAO tallies cost-effective interventions

By

Half-measures, like diabetes educational materials without a part B, fared poorly.

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

By

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters